This is a study to investigate the reliability, ruggedness and safety of the top mounted actuation indicator (TMAI) when used with Levalbuterol HFA MDI.
This is an open-label, multicenter, TMAI study with Levalbuterol HFA MDI in adult and pediatric subjects with asthma or COPD. Period I: One week, open-label, run-in period during which subjects must have asthma or COPD symptoms requiring use of, as needed, Levalbuterol HFA MDI(without TMAI) on at least half of the days \[4-12 actuations on a single day\]. Period II: Nine week, open-label period during which subjects will use the Levalbuterol HFA MDI with TMAI PRN. The total study duration for a subject will not exceed 10 weeks. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
150
Levalbuterol HFA MDA with top mounted actuation indicator
Unnamed facility
Encinatas, California, United States
Unnamed facility
Huntington Beach, California, United States
The difference between the number of actuations estimated via canister weight and the number of actuations recorded byt eh TMAI.
Time frame: 10 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Mesa, California, United States
Unnamed facility
Orange County, California, United States
Unnamed facility
Riverside, California, United States
Unnamed facility
San Diego, California, United States
Unnamed facility
San Jose, California, United States
Unnamed facility
Viejo, California, United States
Unnamed facility
Walnut Creek, California, United States
Unnamed facility
Tamarac, Florida, United States
...and 16 more locations